This Cardio Diabetes Master Class was aimed to be a dynamic meeting with state of the art lectures, clinical debates and practical workshops. THE CMC is an ongoing educational initiative that will provide support to clinicians intheir daily clinical management of cardiovascular risk and diabetes. The program provided an optimal balance between updates in forefront science and clinical dialogue, with involvement of international thought leaders.

The educational objectives of the program were:

• To explore mechanisms and common pathways underlying the development of cardiovascular disease and diabetes
• To review and discuss the importance of glucose management and the rationale for early intervention strategies in patients with diabetes
• To discuss the role of anti-diabetic therapy, in particular the use of DPP4 inhibitors and TZD’s, in a riskbased intervention strategy that targets glucose control and cardiovascular risk factors
• To discuss therapies that work through other insulin-related mechanisms, including insulin resistance in order to reduce the incidence of cardiovascular events; especially in high-risk patient populations with a history of an ACS event and multiple risk factors
• To evaluate the current guidelines for the management of patients with diabetes and high CV risk, and identify potential novel targets for therapy in this high-risk patient group
• To discuss current and future strategies for practical management and interventions to prevent cardiovascular events in multirisk patients

Agenda

• The changing landscape of T2DM management: Balancing new options for glycemic control & outcomes - Prof. Ele Ferrannini, MD - Pisa, Italy
• Managing T2DM in Asia: What are the key issues and considerations for treatment? - Prof. Hyuk-Sang Kwon, MD, Seoul, Korea
• Type 2 diabetes via β-cell dysfunction in East Asian people - Prof. Jeong Hyun Park, MD, Seoul, Korea
• Insulin resistance and beta cell failure: Relevance for diabetes development, prognosis and treatment decisions - Prof. Guntram Schernthaner, MD, Vienna, Austria
• T2DM & cardiovascular risk: What are the considerations for clinical practice? - Prof. Richard Hobbs, MD Oxford, United Kingdom
• Acute Coronary Syndromes & T2DM: Examine the challenges for managing CV risk - Prof. Sanjay Rajagopalan, MD, Cleveland, OH, USA
• Managing CV risk in T2DM beyond glucose - Prof. Richard Hobbs, MD, Oxford, United Kingdom
• The role of pioglitazone in the treatment of Type 2 diabetes: Update 2016 - Prof. Guntram Schernthaner, MD, Vienna, Austria
• Are new Incretin-based treatments changing the fundamentals of diabetes management? - Prof. Sanjay Rajagopalan, MD, Cleveland, OH, USA
• Management of hyperglycaemia in T2DM 2017: A patient-centered approach - Prof. Ele Ferrannini, MD, Pisa, Italy

The Cardio Diabetes Master Class is accredited by the European Board for Accreditation in Cardiology (EBAC) for 9 CME credit hours (day 1: 4 CME credits, day 2: 5 CME credits)

Funding

This meeting is funded by an unrestricted educational grant provided by Takeda Pharmaceuticals